Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | FLT4 | P35916 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | VCP | P55072 | 5/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23553599 | 0.81 | GSK3B (0.47) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL26307279 | 0.78 | FLT1 (0.52) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL23540014 | 0.76 | VCP (0.69) | TRPV1FLT1FLT4KDRVCP | |
| SCHEMBL23540651 | 0.76 | VCP (0.69) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL23539561 | 0.76 | CACNA1B (0.46) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL23540017 | 0.74 | VCP (0.53) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL22925621 | 0.74 | ALOX5 (0.51) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL26312233 | 0.73 | VCP (0.47) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL22925652 | 0.72 | TRPV1 (0.50) | GSK3BTRPV1FLT1FLT4KDR | |
| SCHEMBL23554064 | 0.71 | VCP (0.54) | TRPV1FLT1FLT4KDRVCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |